alloreactive

alloreactive

/al·lo·re·ac·tive/ (-re-ak´tiv) pertaining to the immune response in reaction to a transplanted allograft.

alloreactive

(al″ō-rē-ak′tiv) [ allo- + reactive]
Pert. to certain classes of T lymphocytes, immunologically reactive against a transplanted tissue or organ.
References in periodicals archive ?
Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells.
a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces that its lead product inventor, Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, is providing the following presentation: "Donor lymphocytes selectively photodepleted of alloreactive T cells can fight infections without causing GVHD" at the Haploidentical Transplantation 2013 forum in Metairie/New Orleans on December 5, 2013 prior to the annual meeting of the American Society of Hematology (ASH).
In the skin and GI tissue affected by GVHD, the mechanism of apoptosis is likely similar and caused by alloreactive T lymphocytes targeted to alloantigen on recipient tissue.
Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels.
Anti-C5 mAb Plus Low Dose CTLA4 Ig Inhibit Alloreactive T Cells and Prolong Heart Graft Survival in Mice,"
The induction of increased histocompatibility antigens and leukocyte adhesion molecule expression on tissues such as bile ducts identifies these cells as the targets for the alloreactive donor T-cells.
Alloreactive T-cell recognition of bovine major histocompatibility complex class II products defined by one-dimensional isoelectric focusing.
Subsequent experiments addressed whether PRN treatment of CTLs directly inhibits their activation and revealed that 1[degrees] alloreactive CTLs exposed to PRN are unimpaired in their proliferative response and only marginally inhibited in their lytic activity.
Instead of getting a full complement of T cells from the donor, he said, patients will receive T cells that have been selectively depleted of the alloreactive T cells that researchers believe cause GVHD.
Alloreactive Tc1 and Tc2 cells, harvested from C57BL/B6 (B6, H-2b), were suspended in CM and stimulated with either APC or CD3/CD28 beads.